AU2002311573A1 - Polymorphism in the eosinophil cationic protein (ecp) used in the treatment of e.g. cancer - Google Patents
Polymorphism in the eosinophil cationic protein (ecp) used in the treatment of e.g. cancerInfo
- Publication number
- AU2002311573A1 AU2002311573A1 AU2002311573A AU2002311573A AU2002311573A1 AU 2002311573 A1 AU2002311573 A1 AU 2002311573A1 AU 2002311573 A AU2002311573 A AU 2002311573A AU 2002311573 A AU2002311573 A AU 2002311573A AU 2002311573 A1 AU2002311573 A1 AU 2002311573A1
- Authority
- AU
- Australia
- Prior art keywords
- ecp
- polymorphism
- cancer
- treatment
- cationic protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/27—Endoribonucleases producing 3'-phosphomonoesters (3.1.27)
- C12Y301/27001—Ribonuclease T2 (3.1.27.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0111194.7 | 2001-05-08 | ||
GB0111194A GB0111194D0 (en) | 2001-05-08 | 2001-05-08 | Sequences |
PCT/IB2002/002555 WO2002089829A2 (en) | 2001-05-08 | 2002-05-08 | Polymorphism in the eosinophil cationic protein (ecp) used in the treatment of e.g. cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2002311573A1 true AU2002311573A1 (en) | 2002-11-18 |
Family
ID=9914200
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002311573A Abandoned AU2002311573A1 (en) | 2001-05-08 | 2002-05-08 | Polymorphism in the eosinophil cationic protein (ecp) used in the treatment of e.g. cancer |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2002311573A1 (en) |
GB (1) | GB0111194D0 (en) |
WO (1) | WO2002089829A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113373218A (en) * | 2021-08-04 | 2021-09-10 | 杭州浙大迪迅生物基因工程有限公司 | Primer group and kit for detecting mRNA expression of human eosinophil cationic protein |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2600108A1 (en) * | 2004-03-03 | 2005-09-15 | Chaker N. Adra | Granulocyte subtype-selective receptors and ion channels and uses thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0001706D0 (en) * | 2000-05-09 | 2000-05-09 | Astrazeneca Ab | sequences |
-
2001
- 2001-05-08 GB GB0111194A patent/GB0111194D0/en not_active Ceased
-
2002
- 2002-05-08 WO PCT/IB2002/002555 patent/WO2002089829A2/en not_active Application Discontinuation
- 2002-05-08 AU AU2002311573A patent/AU2002311573A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113373218A (en) * | 2021-08-04 | 2021-09-10 | 杭州浙大迪迅生物基因工程有限公司 | Primer group and kit for detecting mRNA expression of human eosinophil cationic protein |
Also Published As
Publication number | Publication date |
---|---|
GB0111194D0 (en) | 2001-06-27 |
WO2002089829A2 (en) | 2002-11-14 |
WO2002089829A3 (en) | 2003-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002352799A1 (en) | Methods for evaluating drug-resistance gene expression in the cancer patient | |
MXPA03007983A (en) | Process for the preparation of middle distillates. | |
HK1033278A1 (en) | Pharmaceutical preparation for use in anti-asthma therapy. | |
MXPA03007197A (en) | Therapeutic binding molecules. | |
ZA200205191B (en) | LIV-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer. | |
AU2001288101A1 (en) | Ultrasonic beauty treatment probe | |
ZA200202822B (en) | Oncolytic combinations for the treatment of cancer. | |
AU2002364607A1 (en) | Novel ligand involved in the transmigration of leukocytes . | |
AU2002368044A1 (en) | Co-stimulatory molecules | |
MXPA03008582A (en) | Agents and methods for treatment of cancer. | |
AU2002244055A1 (en) | Fra-1 expression in brain cancer | |
AUPR974001A0 (en) | Liquid heater | |
AU2002311573A1 (en) | Polymorphism in the eosinophil cationic protein (ecp) used in the treatment of e.g. cancer | |
AU3556800A (en) | Expression of dna or proteins in (c. elegans) | |
AU2002305138A1 (en) | Methods and materials for cancer treatment | |
AU2003249999A1 (en) | 1,4,7,10-tetraazacyclododecanes as modulators of the guanine-binding protein for treating tumours | |
AU2003255504A1 (en) | Use of 6 amino-quinoline-5, 8 quinones and nucleic acids associated with senescence for the treatment of tumors | |
HK1049477A1 (en) | Apparatus for beauty treatment. | |
AU2002329425A1 (en) | Dna sequencer | |
AU2002302838A1 (en) | Cancer associated protein | |
AU2002336185A1 (en) | Tcmp 03 protein for use in cancer therapy | |
AU2001292788A1 (en) | Remote-on-the-spot credit processing | |
AU2002242505A1 (en) | Tumor associated proteins | |
ZA200306403B (en) | Cancer treatment. | |
AU2002357468A1 (en) | Use of 2-acylindoles in the treatment of tumors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |